The discovery of Fluroxene in depression treatment

Abstract

Depression, particularly major depressive disorder (MDD), has become the world's most frequent mental illness. As the demand for antidepressant medication expanded, monoamine-oxidase inhibitors (MAOIs) were explored first, followed by selective serotonin reuptake inhibitors (SSRIs). One of the most widely recommended SSRIs for the treatment of major depression is fluoxetine (MDD). Fluoxetine has recently been in marketing and therapy, and it has already gone through multiple stages. This document provides an overview of fluoxetine, including its mechanism of action and typical adverse effects. Furthermore, the purpose of this work is to suggest the discovery method (phases I, II, and III), as well as to finish the processes involving sample size, type, and designation. The comparison experiments were taken to suggest how effective the fluoxetine was with the addition of other pharmacies. This review focused on the discovery of Fluroxene in depression treatment.